The HFA at ESC Congress 2022

2021 ESC HF Guidelines: implementation in daily practice

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and prevention of sudden cardiac death

2022 ESC Guidelines on cardio-oncology

Acute hospitalised heart failure: recent positive trials and their clinical relevance 

How to treat a patient with heart failure and a left ventricular ejection fraction (LVEF) > 40%

Heart failure with declining, improved, preserved and normal/supranormal ejection fraction – managing a changing landscape

Heart failure and secondary mitral regurgitation: all you need to know

The management challenge of atrial fibrillation in HFrEF and HFpEF

Quality of life in patients with heart failure

Innovations in drug treatment 

Latest science in heart failure 1

Latest science in heart failure 2

'Inotropes' for the treatment of heart failure remain dead and buried!

Ejection fraction no longer determines the management of heart failure

Session 2

Session 4: SGLT2 inhibition in heart failure

Session 8: Important clinical trial updates 

Early management of acute heart failure

ESC Rene Laennec Lecture in Clinical Cardiology

How to treat HFpEF in 2022 and beyond 

How to manage advanced heart failure - Joint session with the Japanese Circulation Society (JCS)

 Heart failure: what does the future hold? - Joint session with the Mexican Society of Cardiology (MSC)

 Prediction and management for cardiac dysfunction related to cancer therapy - Joint session with the Japanese Circulation Society (JCS)